General Regeneratives Overview

  • Founded
  • 2007
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $15M
Latest Deal Amount
  • Investors
  • 1

General Regeneratives General Information


Developer of therapeutic and diagnostic drugs intended to provide new treatment for disease. The company applies "Prometheus Technology" to uncover the mechanisms governing disease self-healing on various organs and uses genetic engineering, protein, and antibody engineering to produce novel recombinant proteins and antibodies, enabling to discover functional genes critical for disease self-healing and accelerate the development of new biologics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Room 118, No. 6, Lane 898
  • Harley Road, China (Shanghai) Pilot Free Trade Zone
  • Shanghai, 201203
  • China
+86 021 0000 0000 000. 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

General Regeneratives Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 18-Apr-2017 $15M 0000 Completed Startup
1. Early Stage VC Completed Startup
To view General Regeneratives’s complete valuation and funding history, request access »

General Regeneratives Executive Team (1)

Name Title Board Seat Contact Info
Wei Han General Manager, Board Member & Founder
To view General Regeneratives’s complete executive team members history, request access »

General Regeneratives Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Morningside Group Venture Capital Minority 000 0000 000000 0
To view General Regeneratives’s complete investors history, request access »